Involving Rna As A Starting Material Or Intermediate Patents (Class 435/91.51)
  • Patent number: 7270980
    Abstract: Compounds and methods for diagnosing prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. The inventive polypeptides may be used to generate antibodies useful for the diagnosis and monitoring of prostate cancer. Nucleic acid sequences for preparing probes, primers, and polypeptides are also provided.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: September 18, 2007
    Assignee: Corixa Corporation
    Inventors: Jiangchun Xu, Davin C. Dillon, Jennifer Lynn Mitcham
  • Patent number: 7252941
    Abstract: Methods of obtaining faithful expression libraries from tissue samples comprise extraction of RNA from intact tissue cultured in three-dimensional sponge-gel based histocultures.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: August 7, 2007
    Assignee: AntiCancer, Inc.
    Inventors: Ping Jiang, Mingxu Xu, Yuying Tan
  • Patent number: 7214490
    Abstract: The presently claimed invention provides methods and kits for amplifying a target sequence from within a nucleic acid population. The presently claimed invention provides selection probes which are complementary to at least a portion of said target sequence and mechanisms for adding a probe sequence to the 3? end of a target sequence that is hybridized to a selection probe. The added 3? probe sequence and a probe sequence added at the 5? end of the target by adaptor ligation allow for selective amplification of the target sequence.
    Type: Grant
    Filed: September 2, 2003
    Date of Patent: May 8, 2007
    Assignee: Affymetrix, Inc.
    Inventors: Xing Su, Shoulian Dong
  • Patent number: 7205130
    Abstract: The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense and antisense orientation, which are useful for the delivery and expression of a combination of genetic effector types to host cells. Methods for producing these libraries through bi-directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: April 17, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James Lorens, Jakob M. Bogenberger
  • Patent number: 7202028
    Abstract: A method of detecting two different target molecules through a single electrode is carried out by (a) providing a conductive oxidation-reduction reaction detection electrode; (b) contacting a sample suspected of containing a first and second target molecule to the electrode under conditions in which the first and second target molecules are deposited on the electrode, wherein the first target molecule comprises a first label and the second target molecule comprises a second label; (c) contacting to the electrode a first transition metal complex that oxidizes the first preselected label in a first oxidation-reduction reaction and a second transition metal complex that oxidizes the first and second labels in a second oxidation-reduction reaction, with the first and second oxidation-reduction reactions producing different detectable signals; (d) detecting the presence of the first target molecule by detecting the first oxidation-reduction reaction; and (e) detecting the presence of the second target molecule by
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: April 10, 2007
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: H. Holden Thorp, Ivana V. Yang, David H. Stewart, John W. Groelke, Veronika A. Szalai
  • Patent number: 7189512
    Abstract: The present invention relates to methods for identifying variations that occur in the genome of an organism. In particular, the present invention relates to identifying variations without the need for specialized oligonucleotides complementary to each SNP and without a priori knowledge of the sequence or position of the variants.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: March 13, 2007
    Inventors: Noga Porat, Boaz Porat
  • Patent number: 7163789
    Abstract: The invention concerns a method for the diagnosis and/or the follow up of the evolution of cancer comprising the analysis of the RNA components of the telomerase enzyme present in the plasma or serum of the blood.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: January 16, 2007
    Inventors: Xu Qi Chen, Maurice Stroun, Philippe Anker
  • Patent number: 7153672
    Abstract: The present invention relates to a method of preparing a cDNA molecule which includes: contacting an RNA molecule, in the presence of dNTPs, with a non-LTR retrotransposon protein or polypeptide having reverse transcriptase activity under conditions effective for production of a cDNA molecule complementary to the RNA molecule, the contacting being carried out in the absence of a target DNA molecule of the non-LTR retrotransposon protein or polypeptide; and isolating the cDNA molecule. The preferred non-LTR retrotransposon protein or polypeptide is an R2 protein or polypeptide.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: December 26, 2006
    Assignee: University of Rochester
    Inventors: Thomas H. Eickbush, Arkadiusz Bibillo
  • Patent number: 7129045
    Abstract: Methods of detecting or measuring the activity of polynucleotide kinase are disclosed as well as methods of detecting an analyte in an assay using polynucleotide kinase as a label on a member of a specific binding pair. The methods rely on the phosphorylation of an oligonucleotide followed by ligation of the oligonucleotide 5?-phosphate onto another template-bound oligonucleotide. The presence of the ligated product signals the presence of polynucleotide kinase. In preferred embodiments, phosphorylation of an oligonucleotide enables the consecutive ligation of a set of oligonucleotides. The oligonucleotides so ligated can be detectably labeled with, for example, other enzymes to provide highly sensitive detection methods.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: October 31, 2006
    Assignee: Lumigen, Inc.
    Inventor: Hashem Akhavan-Tafti
  • Patent number: 7122304
    Abstract: The invention relates to storage of nucleic acid (particularly mRNA) on a solid support and to using such nucleic acid in nucleic acid synthesis or amplification reactions. In a preferred aspect, the invention provides synthesis of cDNA and cDNA libraries.
    Type: Grant
    Filed: November 30, 2000
    Date of Patent: October 17, 2006
    Assignee: Whatman, Inc.
    Inventors: Mindy D. Goldsborough, Donna K. Fox
  • Patent number: 7074558
    Abstract: This invention provides for a novel amplification procedure for nucleic acid. The method uses a wild type or mutant RNA polymerase designed to transcribe both deoxyribonucleotides and ribonucleotides.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: July 11, 2006
    Assignee: PBI Technology, Inc.
    Inventors: Paul V. Haydock, Jack U'ren
  • Patent number: 7074596
    Abstract: The ability to synthesize capped RNA transcripts in vitro has been of considerable value in a variety of applications. However, one-third to one-half of the caps have, until now, been incorporated in the reverse orientation. Such reverse caps impair the translation of in vitro-synthesized mRNAs. Novel cap analogues, such as P1-3?-deoxy-7-methylguanosine-5?P3-guanosine-5?triphosphate and P1-3?-O,7-dimethylguanosine-5?P3-guanosine-5?triphosphate, have been designed that are incapable of being incorporated into RNA in the reverse orientation. Transcripts produced with SP6 polymerase using “anti-reverse” cap analogues were of the predicted length. Analysis of the transcripts indicated that reverse caps were not formed. The in vitro translational efficiency of transcripts with the novel “anti-reverse” cap analogues was significantly higher than that of transcripts formed with conventional caps.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: July 11, 2006
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Edward Darzynkiewicz, Robert E. Rhoads, Janusz Stepinski
  • Patent number: 7029881
    Abstract: Method and apparatus for constructing a cDNA library by hybridizing mRNA with oligo (dT) on a support and treating with a reverse transcriptase to immobilized complementary DNA, or for constructing a gDNA library by ligating a double-stranded chromosomal DNA library with an oligonucleotide on a support having a restriction enzyme site and then immobilizing the gDNA library.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: April 18, 2006
    Assignees: Nihon Parkerizing Hiroshima Co., Ltd., Toyo Kohan Co., Ltd.
    Inventors: Kojiro Takahashi, Osamu Takai, Michifumi Tanga
  • Patent number: 7005278
    Abstract: The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing Dihydropyrimidine dehydrogenase (DPD) expression levels in tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU based therapies by examination of the amount of DPD mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pairs DPD3A and DPD3B and methods comprising their use for detecting levels of Dihydropyrimidine dehydrogenase (DPD) mRNA.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: February 28, 2006
    Inventor: Kathleen D. Danenberg
  • Patent number: 6998232
    Abstract: There is provided a method of diagnosing the presence of bladder cancer in a patient by analyzing a tissue sample from the patient for the presence of a least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Also provided by the present invention is a polynucleotide sequence whose expression is indicative of bladder cancer. A marker for bladder cancer is also provided. There are also provided methods of diagnosing bladder cancer by screening for the presence of at least one expressed gene wherein the presence of the expressed gene is indicative of bladder cancer. Methods of treating and regulating bladder cancer-associated pathologies by administering to a patient a therapeutically effective amount of chemical compound are also provided.
    Type: Grant
    Filed: April 4, 2001
    Date of Patent: February 14, 2006
    Assignee: Quark Biotech, Inc.
    Inventors: Elena Feinstein, Orna Mor
  • Patent number: 6994969
    Abstract: The present invention is in the field of nucleic acid-based diagnostic assays. More particularly, it relates to methods useful for the “diagnostic sequencing” of regions of sample nucleic acids for which a prototypic or reference sequence is already available (also referred to as “re-sequencing”), or which may be determined using the methods described herein. This diagnostic technology is useful in areas that require such re-sequencing in a rapid and reliable way: (i) the identification of the various allelic sequences of a certain region/gene, (ii) the scoring of disease-associated mutations, (iii) the detection of somatic variations, (iv) studies in the field of molecular evolution, (v) the determination of the nucleic acid sequences of prokaryotic and eukaryotic genomes, (vi) identifying one or more nucleic acids in one or more biological samples', (vii) and determining the expression profile of genes in a biological sample and other areas.
    Type: Grant
    Filed: April 30, 2000
    Date of Patent: February 7, 2006
    Assignee: Methexis Genomics, N.V.
    Inventors: Marc Zabeau, Patrick Stanssens
  • Patent number: 6994963
    Abstract: This invention pertains to a method for generating a pool of nucleic acid fragments useful for in vitro recombination and the creation of novel DNA sequences that encode desirable proteins or enzymes. The invention provides a defined mixture of nucleic acids and methods for use in the synthesis, mutagenesis, and recombination of nucleic acids. Nucleic acids may be synthesized by creating a nucleic acid extension ladder, annealing the extension ladder to template nucleic acids, and further extending the ladder of nucleic acids. The invention also relates to methods for performing repeated cycles of synthesis for the purpose of mutagenesis or recombination, methods for producing mutant peptides and proteins from the mutagenized or recombined nucleic acids, and methods for selecting a peptide, polypeptide or protein having altered biological activities.
    Type: Grant
    Filed: July 10, 2000
    Date of Patent: February 7, 2006
    Assignee: Ambion, Inc.
    Inventors: George L. Murphy, Robert A. Setterquist, Andrew D. Ellington
  • Patent number: 6986988
    Abstract: A method for enrichment of natural antisense mRNA which involves hybridization of cDNA obtained from sense RNA with cDNA obtained from antisense RNA, followed by DNA polymerase treatment of the sense-antisense hybrid DNA molecule. A natural antisense library can be generated by cloning of sense-antisense hybrid DNA molecules in a vector.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: January 17, 2006
    Assignee: Quark Biotech, Inc.
    Inventors: Shlomit Gilad, Paz Einat, Avital Grossman
  • Patent number: 6967016
    Abstract: The invention relates to the diagnosis of disease or the determination of functioning of cellular organisms, being of multi-cellular or unicellular nature, being visible by the naked eye or being a microorganism. The invention provides a method for determining functioning of a cellular organism comprising determining the relative ratio of a first endosymbiont cellular organelle nucleic acid and/or gene product thereof in a sample obtained from the organism in relation to the amount of a second nucleic acid and/or gene product thereof.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: November 22, 2005
    Assignee: PrimaGen Holding B.V.
    Inventors: Bob van Gemen, Eveline Catherina A. C. Timmermans, Anthonij de Ronde, Irene Johanna M. Dobbelaer
  • Patent number: 6958245
    Abstract: A method and apparatus for the manipulation of colloidal particulates and biomolecules at the interface between an insulating electrode such as silicon oxide and an electrolyte solution. Light-controlled elektrokinetic assembly of particles near surfaces relies on the combination of three functional elements, the AC electric field-induced assembly of planar aggregates; the patterning of the electrolyte/silicon oxide/silicon interface to exert spatial control over the assembly process; and the real-time control of the assembly process via external illumination. The present invention provides a set of fundamental operations enabling interactive control over the creation and placement of planar arrays of several types of particles and biomolecules and the manipulation of array shape and size. The present invention enables sample preparation and handling for diagnostic assays and biochemical analysis in an array format, and the functional integration of these operations.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: October 25, 2005
    Assignee: Bioarray Solutions Ltd.
    Inventors: Michael Seul, Alice X. Li
  • Patent number: 6939671
    Abstract: This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)—RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: September 6, 2005
    Assignee: Oncomedx, Inc.
    Inventor: Michael S. Kopreski
  • Patent number: 6916634
    Abstract: This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)—RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: July 12, 2005
    Assignee: OncoMEDx, Inc.
    Inventor: Michael S. Kopreski
  • Patent number: 6913884
    Abstract: The present invention relates to detection or genotyping (or other sample analysis) of target nucleic acids following immobilization of the target nucleic acids onto a surface. The target nucleic acids can be re-used multiple times, thus conserving sample materials and simplifying sample preparation.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: July 5, 2005
    Assignee: Illumina, Inc.
    Inventors: John R. Stuelpnagel, Mark S. Chee
  • Patent number: 6908618
    Abstract: A method of producing an attenuated bovine respiratory syncytial virus (BRSV) having increased or decreased transcription and/or replication, as compared to a wild-type BRSV, including the steps of inserting a synthetic cDNA which codes for an infectious BRSV into a host cell, wherein the cDNA is operably-linked to a promoter; expressing the cDNA in the host cell to produce the infectious BRSV; and thereafter introducing at least one site-specific RNA point mutation on the P gene of the BRSV. An attenuated BRSV and vaccine produced by the method are also included.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: June 21, 2005
    Assignee: University of Maryland
    Inventor: Siba K. Samal
  • Patent number: 6905828
    Abstract: The present invention relates to fluorescent probes which can be used in multicolor fluorescence in situ hybridization, and mainly chromosome painting. The probes intended for labeling a chromosome are such that they are composed of a set of DNA segments which are more represented in certain chromosome bands and which are obtained by IRS-PCR amplification from said chromosomes using PCR primers specific for the repeated and dispersed Alu and LINE DNA sequences. The invention comprises, in addition, methods of producing said probes, multicolor FISH methods which can use said probes as well as diagnostic kits comprising them. Finally, the invention comprises combinations of fluorophores and optical filters.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: June 14, 2005
    Assignee: Genset S.A.
    Inventor: Dorra Cherif
  • Patent number: 6893847
    Abstract: The present invention provides oligonucleotides for detecting Salmonella toxin gene invA mRNA and stn mRNA which oligonucleotides specifically bind to invA mRNA or stn mRNA at a relatively low temperature (for example, 41° C.) and at a constant temperature, and a process of amplifying Salmonella toxin gene invA mRNA or stn mRNA and a method of detecting the same using the oligonucleotides.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: May 17, 2005
    Assignee: Tosoh Corporation
    Inventors: Akihiro Yokoyama, Takahiko Ishiguro
  • Patent number: 6890712
    Abstract: This invention relates to an improved process for detecting and quantifying a desired nucleic acid sequence. The process involves synthesizing single stranded RNA, single stranded DNA, double-stranded DNA followed by detection using an electrochemiluminescent labeled binding species.
    Type: Grant
    Filed: January 10, 2000
    Date of Patent: May 10, 2005
    Assignee: BioVeris Corporation
    Inventors: John H. Kenten, Rodger Smith
  • Patent number: 6890741
    Abstract: The present invention is directed to sensitive and accurate multiplexed assays for target analyte detection.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: May 10, 2005
    Assignee: Illumina, Inc.
    Inventors: Jian-Bing Fan, John R. Stuelpnagel, Mark S. Chee
  • Patent number: 6867021
    Abstract: The present invention provides a multiplex RT-PCR/PCR method, which enables in a single assay the simultaneous detection of any combination of bovine rotavirus, bovine coronavirus, Cryptosporidium parvum, and optionally, Escherichia coli strains producing K99 pili or heat-stable enterotoxin STa.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: March 15, 2005
    Assignee: Board of Trustees of Michigan State University
    Inventors: Roger K. Maes, Annabel G. Wise
  • Patent number: 6867035
    Abstract: This invention provides a method for selecting a clone of an ES cell containing a mutation in a gene that is expressed in a test cell comprising: (a) providing cDNA obtained by reverse transcription of mRNA of the test cell; (b) providing a collection of cultured ES cells organized into individual clones, wherein each clone is of an ES cell having a mutation in an exon in its genome, the mutation being in a different exon in cells of different clones; (c) providing an array of different single stranded polynucleotides, the polynucleotides being fragments of exons containing mutations in (b); (d) exposing the cDNA to the array under conditions permitting hybridization of polynucleotides in the array to nucleic acids; (e) detecting hybridization of cDNA to a polynucleotide on the array; and, (f) selecting a clone in the collection from which a hybridizing polynucleotide detected at (c) is an exon fragment. This invention also provides a system for testing expression of a gene in a test cell.
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: March 15, 2005
    Assignee: The University of British Columbia
    Inventor: Christopher J. Ong
  • Patent number: 6864050
    Abstract: The amplification of nucleic acids in a single phase can reliably provide products at relatively low cost and labor. A single-phase amplification can also increase the amount of nucleic acids while preserving the relative abundance of the individual nucleic acid species, or portions thereof. A single-phase amplified nucleic acid preparation may be analyzed in a gene expression monitoring system, preferably involving a nucleic acid probe array.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: March 8, 2005
    Assignee: Affymetrix, Inc.
    Inventors: Xing Su, Rolfe C. Anderson
  • Patent number: 6864057
    Abstract: Methods are provide for preparing cDNA corresponding to a mRNA. In the subject methods, a mRNA is first contacted with a mixture of primers under first strand cDNA synthesis conditions. The primer mixture contains primers that have at least 10 contiguous deoxythymidines, a double stranded restriction enzyme recognition sequence near one end and a non-polyA-complementary region near the other end, where the non-polyA-complementary region is -VV, -VTV, -VTTV, -VTTTV, and -VVVVV. The resultant cDNA is modified such that the polyT tail is substantially removed. The modified cDNA is then ligated into a vector. The subject methods find use in a variety of applications, and find particular use in the sequencing of DNA and in the synthesis of cDNA libraries.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: March 8, 2005
    Assignee: Incyte Corporation
    Inventors: Glenn K. Fu, Steven Starnes, Laura L. Stuve
  • Patent number: 6861219
    Abstract: There is a tremendous need for high throughput gene expression technology which can efficiently and cheaply identify and accurately isolate different genes expressed between diseased and normal tissues for use in discovering new drugs. The present invention utilizes a combination of biomolecular chemistry methods to eliminate/degrade redundant sequences and fluorescence dye assay to identify these unique sequences from two cell or tissue populations. cDNA from normal or diseased cells or tissues are hybridized with the RNA of the complement normal or diseased cells or tissues. The hybridized cDNA/RNA is incubated with exonucleases, resulting in degradation of all but the single stranded RNA and DNA. RNA are then eliminated using RNase and the remaining DNA which are unique to the sample are amplified.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: March 1, 2005
    Assignee: Genexpress Informatics, Inc.
    Inventors: Shahzi Iqbal, Robert Chin
  • Patent number: 6855523
    Abstract: An improved method allowing for rapid sensitive and standardized detection of a target nucleic acid from a pathogenic microorganism or virus or normal or abnormal gene in a sample is provided. The method involves hybridizing a target nucleic acid to several non-overlapping oligonucleotide probes that hybridize to adjacent regions in the target nucleic acid, the probes being referred to capture/amplification probes and amplification probes, respectively, in the presence of paramagnetic beads coated with a ligand binding moiety. Through the binding of a ligand attached to one end of the capture/amplification probe and the specific hybridization of portions of the probes to adjacent sequences in the target nucleic acid, a complex comprising the target nucleic acid, the probes and the paramagnetic beads is formed. The probes may then ligated together to form a contiguous ligated amplification sequence bound to the beads, which complex may be denatured to remove the target nucleic acid and unligated probes.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: February 15, 2005
    Assignee: Mount Sinai School of Medicine of New York University
    Inventors: David Y. Zhang, Margaret Brandwein, Terence C. H. Hsuih
  • Patent number: 6844155
    Abstract: The invention provides methods for detecting contamination in a PCR reaction. Methods of the invention are especially useful for detection of contamination in heterogeneous samples containing a rare nucleic acid to be detected.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: January 18, 2005
    Assignee: Exact Sciences Corporation
    Inventor: Anthony P. Shuber
  • Patent number: 6841128
    Abstract: The present invention provides a DNA base sequencing system having a compact, simple and convenient structure. In one embodiment of the present invention, a reaction chamber module for pyrosequencing in which a multiple number of reaction vessels (reaction chambers) 10 and reagent-introducing narrow tubes 6 are integrated is formed in a device board 5. Reagents held in reagent reservoirs 1, 2, 3 and 4 mounted separately from this reaction chamber module are introduced into the reaction vessels 10 via reagent-introducing narrow tubes (capillaries) 6. The reagent-introducing narrow tubes (capillaries) 6 at the area of 2 cm from the reaction vessels 10 are structured with narrow capillaries having an inner diameter of about 0.1 mm and the conductance of these capillaries for the reagent solution determines the injection speed of the solution. Using the present invention, many kinds of DNAs can be analyzed simultaneously.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: January 11, 2005
    Assignee: Hitachi, Ltd.
    Inventors: Hideki Kambara, Guohua Zhou, Yuji Miyahara
  • Patent number: 6841363
    Abstract: The invention provides a process for preparing capped mRNAs from an RNA mixture, e.g. whole RNA isolated from a cell or tissue extract, that includes combining in a reaction mixture RNA comprising capped mRNA with a separable affinity matrix having high-affinity eIF4E bound thereto, under conditions sufficient for binding to occur between the high-affinity eIF4E and the capped mRNA, whereby capped mRNA is bound to the affinity matrix, separating the affinity matrix from the reaction mixture, then separating the capped mRNA from the affinity matrix. High affinity eIF4E mutants previously described are employed in the process as well as a novel mutant disclosed and claimed herein. The mRNA preparation process is based on isolation of 5?-capped mRNA. The mRNA molecules thus isolated have intact sequences encoding the NH2-terminal ends of the proteins they encode, unlike those isolated by prior methods.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: January 11, 2005
    Assignee: Emory University
    Inventor: Curt H. Hagedorn
  • Patent number: 6841348
    Abstract: This invention provides methods for discovering maintenance genes and for using maintenance genes. In one embodiment, the expression of at least three maintenance genes are measured and used as reference (or control) for comparing the expression of target genes in two or more biological samples.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: January 11, 2005
    Assignee: Affymetrix, Inc.
    Inventors: Janet A. Warrington, Mamatha Mahadevappa, Archana Nair
  • Patent number: 6821731
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating prostate cancer. FKBP markers are provided, wherein changes in the levels of expression of one or more of the FKBP markers is correlated with the presence of prostate cancer.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: November 23, 2004
    Assignee: Wyeth
    Inventors: Kimberly A. Gillis, Yixian Zhang
  • Patent number: 6808906
    Abstract: The present invention provides random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in sense orientation. Also provided are random cDNA expression vector libraries, comprising expression vectors which comprise random cDNAs positioned in antisense orientation. Methods for producing these libraries through directional cloning of random cDNAs are also provided. Also provided herein are methods of using these libraries to screen for agents capable of modulating cell phenotype in desirable ways.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: October 26, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Mary Shen, Simon Yu, Xian Wu, Donald Payan
  • Patent number: 6794135
    Abstract: This invention relates to methods of detecting or inferring the presence of malignant or premalignant cells in a human that express 5T4. Provided are methods for detecting 5T4 RNA in blood, plasma, serum, other bodily fluids, cells, and tissues. The invention thereby provides an aid for the detection, diagnosis, monitoring, treatment, or evaluation of neoplastic disease.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: September 21, 2004
    Assignee: Oncomedx, Inc.
    Inventors: Michael S. Kopreski, Christopher D. Gocke
  • Patent number: 6794140
    Abstract: Provided is a preparative method for isolating RNA comprising an oligo- or polynucleotide from a sample, which method comprises: (a) treating the sample with a reactant capable of covalently modifying the 2′-OH position of the ribose rings of the RNA under conditions so that a proportion of the 2′-OH positions of the ribose rings bear a substituent; and (b) preparing isolated RNA therefrom by separating material containing the substituent from the sample on the basis of a property of the substituent.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: September 21, 2004
    Inventor: Andrew Simon Goldsborough
  • Patent number: 6787311
    Abstract: Methods by which a predisposition to Premature Ovarian failure (POF) can be determined. In particular, methods are provided for detecting whether a female has a predisposition to POF with reference to an alteration (mutation) in the gene coding inhibin.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: September 7, 2004
    Assignee: Auckland Uniservices Limited
    Inventor: Andrew N. Shelling
  • Patent number: 6783943
    Abstract: Rolling circle amplification (RCA) has been useful for detecting point mutations in isolated nucleic acids, but its application in cytological preparations has been problematic. By pretreating cells with a combination of restriction enzymes and exonucleases, we demonstrate RCA in solution and in situ to detect gene copy number and single base mutations. It can also detect and quantify transcribed RNA in individual cells, making it a versatile tool for cell-based assays.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: August 31, 2004
    Assignee: The Regents of the University of California
    Inventors: Allen T. Christian, Melissa S. Pattee, Cristina M. Attix, James D. Tucker
  • Patent number: 6777180
    Abstract: The present invention provides a method for isolating a double-stranded cDNA having a nucleotide sequence of a complete open reading frame which comprises: (A) admixing (i) an isolated single-stranded cDNA, (ii) a first primer capable of forming a stem-loop structure, comprising (a) at the 3′ end of the primer, a first random sequence, linked to (b) a second sequence, linked to (c) a third sequence which forms a loop structure, linked to (d) a fourth sequence, at the 5′ end of the first primer, which is complementary to the second sequence, under hybridization conditions sufficient for annealing the first sequence of the first primer to the sequence at the 3′ end of the single-stranded cDNA, and (iii) a polymerase; (B) incubating the mixture from step (A) under suitable conditions for DNA synthesis; and (C) performing a polymerase chain reaction by admixing (i) an aliquot of the mixture from (B), (ii) a second primer which specifically binds to the single-stranded cDNA, (iii) a third primer
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 17, 2004
    Assignee: Trustees of Columbia University in the City of New York
    Inventors: Paul B. Fisher, Dong-Chul Kang
  • Patent number: 6767704
    Abstract: Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach or esophageal cancer are disclosed.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: July 27, 2004
    Assignee: Thomas Jefferson University
    Inventors: Scott A. Waldman, Jason Park, Stephanie Schulz
  • Patent number: 6767536
    Abstract: Isolated and purified Staphylococcus thioredoxin reductases (TrxB) are provided. Polynucleotides encoding the TrxBs, vectors and host cells containing such polynucleotides are also provided. In addition, antibodies reactive with the TrxBs are provided, as are methods of isolating the TrxBs, as well as methods for producing recombinant TrxBs, using TrxBs for screening compounds for TrxB-modulating activity, and detecting Staphylococcus in a test sample.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: July 27, 2004
    Assignee: Ramot at Tel Aviv University Ltd.
    Inventors: Yair Aharonowitz, Ilya Borovok, Gerald Cohen, Orit Uziel, Leonard Katz
  • Patent number: 6762021
    Abstract: The present invention provides a reagent for diagnosing Crohn's disease, which contains at least one member selected from the group consisting of a group of substances having a specific affinity for a protein (or a gene thereof) whose expression is potentiated in a lesion-specific manner, such as a substance having a specific affinity for PP6 regulated by IL-2 (or a gene thereof), a substance having a specific affinity for TNIK (or a gene thereof), a substance having a specific affinity for FLIP (or a gene thereof), a substance having a specific affinity for GR&agr; (or a gene thereof) and the like. By taking note of a gene whose expression is potentiated in a lesion-specific manner, and examining the behavior thereof by the use of this diagnostic reagent, the disease can be diagnosed easily and quickly.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: July 13, 2004
    Assignee: Mitsubishi Pharma Corporation
    Inventors: Katsushi Tokunaga, Naoyuki Tsuchiya
  • Patent number: 6759217
    Abstract: The methods of the invention detect epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof in blood plasma, serum, and other bodily fluids. The inventive methods are useful for detection, diagnosis, monitoring, treatment, or evaluation of neoplastic disease.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: July 6, 2004
    Assignee: OncoMEDx, Inc.
    Inventor: Michael S. Kopreski
  • Patent number: 6740510
    Abstract: The presently claimed invention provides methods for amplifying a DNA target sequence. One embodiment of the present invention provides robust methods for amplification of target sequences. In a first aspect of the invention, a method for designing primer pairs for the amplification reaction is provided. In a further aspect of the invention, reagents and cycling parameters for the amplification reaction are provided.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: May 25, 2004
    Assignee: Perlegen Sciences, Inc.
    Inventors: Curtis R. Kautzer, Nila Patil, Coleen R. Hacker, David P. McDonough